161 related articles for article (PubMed ID: 37750075)
1. The antihypertensive felodipine shows synergistic activity with immune checkpoint blockade and inhibits tumor growth via NFAT1 in LUSC.
Liang SY; Xiao HK
Open Med (Wars); 2023; 18(1):20230801. PubMed ID: 37750075
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analyses of a CD8
Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
[TBL] [Abstract][Full Text] [Related]
3. Verapamil modulates NFAT2 to inhibit tumor growth and potentiates PD1ab immune checkpoint inhibitor therapy in cervical cancer treatment.
Liao YQ; Fang BB; Wu QX; Dong WY; Deng GM
J Recept Signal Transduct Res; 2023 Aug; 43(4):93-101. PubMed ID: 38070127
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation and migration and is associated with dismal prognosis and immunity in lung squamous cell carcinoma.
Guo Q; Wu CY; Jiang N; Tong S; Wan JH; Xiao XY; Mei PY; Liu HS; Wang SH
Front Immunol; 2022; 13():986447. PubMed ID: 36544782
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol improves the cytotoxic effect of CD8 +T cells in the tumor microenvironment by regulating HMMR/Ferroptosis in lung squamous cell carcinoma.
Shan G; Minchao K; Jizhao W; Rui Z; Guangjian Z; Jin Z; Meihe L
J Pharm Biomed Anal; 2023 May; 229():115346. PubMed ID: 37001272
[TBL] [Abstract][Full Text] [Related]
6. FUBP1 promotes the proliferation of lung squamous carcinoma cells and regulates tumor immunity through PD-L1.
Yu J; Peng W; Xue Y; Li Y; Yang L; Geng Y
Allergol Immunopathol (Madr); 2022; 50(5):68-74. PubMed ID: 36086966
[TBL] [Abstract][Full Text] [Related]
7. [Exploration of the Perturbation of PKIG in Lung Squamous Cell Carcinoma and the Role in Tumor Microenvironment Based on Bioinformatics Method].
Liu Q; Li H; Li B; Ren M; Li Z; Chen Y; Zheng Z; Meng Y; Feng H
Zhongguo Fei Ai Za Zhi; 2023 Jul; 26(7):523-537. PubMed ID: 37653016
[TBL] [Abstract][Full Text] [Related]
8. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis.
Zhang LX; Gao J; Long X; Zhang PF; Yang X; Zhu SQ; Pei X; Qiu BQ; Chen SW; Lu F; Lin K; Xu JJ; Wu YB
Mol Cancer; 2022 May; 21(1):110. PubMed ID: 35525959
[TBL] [Abstract][Full Text] [Related]
9. Integrative Analysis of Pyroptosis-Related Prognostic Signature and Immunological Infiltration in Lung Squamous Cell Carcinoma.
Luo P; Jiang Y; Ding S; Jiang S; Tang R; Tang Z
Biomed Res Int; 2022; 2022():4944758. PubMed ID: 35692583
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
11. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
[TBL] [Abstract][Full Text] [Related]
13. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
14. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
[TBL] [Abstract][Full Text] [Related]
15. Effects of Lipid Metabolism-Related Genes PTGIS and HRASLS on Phenotype, Prognosis, and Tumor Immunity in Lung Squamous Cell Carcinoma.
Lei K; Liang R; Tan B; Li L; Lyu Y; Wang K; Wang W; Wang K; Hu X; Wu D; Lin H; Wang M
Oxid Med Cell Longev; 2023; 2023():6811625. PubMed ID: 36703911
[TBL] [Abstract][Full Text] [Related]
16. GABRP is a Promising Prognostic Biomarker and Associated with Immune Cell Infiltration in Lung Squamous Cell Carcinoma.
Fu J; Lin J; Zeng X; Li G; Wei Y; Xian L
Pharmgenomics Pers Med; 2023; 16():357-371. PubMed ID: 37091829
[TBL] [Abstract][Full Text] [Related]
17. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
[TBL] [Abstract][Full Text] [Related]
18. An Integrative Analysis Identifying RAB40C as an Oncogenic Immune Protein and Prognostic Marker of Lung Squamous Cell Carcinoma.
Wu H; Dong X; Liao L; Huang L
Pharmgenomics Pers Med; 2022; 15():525-537. PubMed ID: 35645578
[TBL] [Abstract][Full Text] [Related]
19. Silencing GOLGA8B inhibits cell invasion and metastasis by suppressing STAT3 signaling pathway in lung squamous cell carcinoma.
Li Z; Li Y; Li N; Shen L; Liu A
Clin Sci (Lond); 2022 Jun; 136(11):895-909. PubMed ID: 35593117
[TBL] [Abstract][Full Text] [Related]
20. Identification and Validation of a Four-Gene Ferroptosis Signature for Predicting Overall Survival of Lung Squamous Cell Carcinoma.
Wang Q; Chen Y; Gao W; Feng H; Zhang B; Wang H; Lu H; Tan Y; Dong Y; Xu M
Front Oncol; 2022; 12():933925. PubMed ID: 35912252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
